Soumya Ray, Ph.D.

Soumya recently joined as interim CTO of New Equilibrium Biosciences where he also serves as a board observer. He spends the remainder of his time as an independent consultant helping in company creation across multiple venture firms by proving computation chemistry support through his consulting firm, 3-Dimensional consulting. Until recently, Soumya Ray was an EIR at RA, co-founding team member of two Stealth NewCo and an integral part of the drug discovery team that led the creation of two RA backed degrader companies. At RA, he worked closely with the investment team on computation chemistry and machine learning opportunities. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. During his drug discovery career, he supported and contributed to over 75 drug discovery programs, which lead to nine development candidates currently in various stages of clinical trials. He has numerous academic publications, inventorship on patents and serves as reviewer for multiple journals and NIH grants committee. Soumya obtained his PhD in X-ray Crystallography and Biophysics from the Rockefeller University in New York.